Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™
Launched by HENOGEN · Mar 7, 2007
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Subjects who received complete full vaccination with Henogen HBV adjuvanted vaccine or Fendrix™ will participate in this persistence study for three long-term time points (12, 24 and 36 months after the first dose of primary vaccination). Blood sampling will be done at each time point to measure immune persistence.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent obtained from the subject/ from the parent/ guardian of the subject.
- • Subjects who completed the full course of primary vaccination.
- Exclusion Criteria:
- • Immunosuppression caused by the administration of parenteral steroids or chemotherapy.
- • Any confirmed or suspected human immunodeficiency virus (HIV) infection.
About Henogen
Henogen is a biopharmaceutical company dedicated to advancing innovative therapies through rigorous clinical research and development. With a focus on cutting-edge technologies and a commitment to improving patient outcomes, Henogen specializes in the development of biologics and vaccines aimed at addressing unmet medical needs. The company leverages its expertise in regulatory compliance and quality assurance to conduct clinical trials that adhere to the highest standards of safety and efficacy. By fostering collaboration with healthcare professionals and research institutions, Henogen strives to contribute significantly to the advancement of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gent, , Belgium
Bruxelles, , Belgium
Aalst, , Belgium
Ath, , Belgium
Baudour, , Belgium
Bruxelles, , Belgium
Charleroi, , Belgium
La Louvière, , Belgium
Leuven, , Belgium
Montigny Le Tilleul, , Belgium
Tournai, , Belgium
Liberec, , Czech Republic
Prague, , Czech Republic
Usti Nad Labem, , Czech Republic
Budapest, , Hungary
Budapest, , Hungary
Kistarcsa, , Hungary
Szombathely, , Hungary
Jihlava, , Czech Republic
Bruxelles, , Belgium
Bruxelles, , Belgium
Ostrava, , Czech Republic
Győr, , Hungary
Patients applied
Trial Officials
Joëlle Nortier, MD, PhD
Principal Investigator
ULB Hôpital Erasme Département de Néphrologie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials